Orchestra BioMed Holdings, Inc. Revenue 2022–2025

Revenue Gross Profit Operating Income EBITDA Net Income EPS Shares Outstanding

Orchestra BioMed Holdings, Inc. annual/quarterly revenue history and growth rate from 2022 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.

Orchestra BioMed Holdings, Inc. revenue for the quarter ending March 31, 2026 was 110000, a 87.33% decrease year-over-year.
Orchestra BioMed Holdings, Inc. revenue for the twelve months ending March 31, 2026 was 2.7 M, a 4.60% decrease year-over-year.
Orchestra BioMed Holdings, Inc. annual revenue for 2025 was 33.5 M, a 1169.22% increase from 2024.
Orchestra BioMed Holdings, Inc. annual revenue for 2024 was 2.6 M, a 4.42% decrease from 2023.
Orchestra BioMed Holdings, Inc. annual revenue for 2023 was 2.8 M, a 21.88% decrease from 2022.
Orchestra BioMed Holdings, Inc. annual revenue for 2022 was 3.5 M.

Revenue

ANNUAL · $B

QUARTERLY · $B

YEAR-OVER-YEAR GROWTH · %

Orchestra BioMed Holdings, Inc. (OBIO) — Frequently Asked Questions

Orchestra BioMed Holdings, Inc. (OBIO) is a publicly traded US company. It has a market capitalization of $195M. In fiscal 2025 it reported revenue of $33M and net income of -$53M. Explore OBIO's stock price, financial statements, earnings history, margins and key ratios below.

What is Orchestra BioMed Holdings, Inc.'s market cap?

Orchestra BioMed Holdings, Inc. (OBIO) has a market capitalization of $195M.

What is the OBIO stock price?

OBIO trades at $4.08 (+1.62% on the day).

How much revenue does Orchestra BioMed Holdings, Inc. make?

Orchestra BioMed Holdings, Inc. reported revenue of $33M in fiscal 2025.

Is OBIO profitable?

In fiscal 2025, Orchestra BioMed Holdings, Inc. reported net income of -$53M.